• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • Our Pillars
        • ARIKAYCE®
        • Brensocatib
        • TPIP
        • Early-Stage Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • May 17, 2005
    Insmed Announces Exclusive Option Agreement with UCSF for Series of IGF-1 Receptor Antagonists; Agreement Expands Collaboration on IGF-1 Program in Prostate Cancer
  • May 10, 2005
    Insmed Incorporated Reports Financial Results for First Quarter of 2005
  • May 5, 2005
    Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET)
  • Apr 26, 2005
    Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance
  • Apr 20, 2005
    Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R)
  • Apr 18, 2005
    Patent Infringement Suit Against Insmed Dismissed
  • Apr 13, 2005
    FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
  • Mar 16, 2005
    Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004
  • Mar 15, 2005
    Insmed to Release Fourth Quarter and Year End Financial Results; Wednesday, March 16
  • Mar 15, 2005
    Insmed Announces Completion of $35 Million Financing
  • Mar 10, 2005
    FDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
  • Feb 22, 2005
    Insmed Provides Response to United States Patent Lawsuit; Seeks Immediate Dismissal or Summary Judgment for All Claims
  • Feb 16, 2005
    Insmed Provides Response to UK Patent Lawsuit
  • Jan 7, 2005
    University of Rochester Awarded $6.5 Million to Study Efficacy OF rhIGF-I/rhIGFBP-3, SomatoKine, in the Treatment of Myotonic Dystrophy
  • Jan 3, 2005
    Insmed Submits New Drug Application -NDA- to Seek Regulatory Approval of SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
  • Dec 31, 2004
    Insmed Completes New Drug Application -NDA- for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome; Conference Call Scheduled for 11:00 am January 5, 2005
  • Dec 30, 2004
    Insmed Incorporated Released the Following Statement in Response to Recent Actions by Tercica, Inc.
  • Dec 21, 2004
    Insmed Incorporated Released the Following Statement in Response to a Press Release Made Yesterday by Tercica, Inc.
  • Nov 9, 2004
    Insmed Announces Expansion of Patent Portfolio in the Treatment of Diabetes; New European Patent Granted for SomatoKine
  • Nov 8, 2004
    Insmed Raises Approximately $8.7 Million in Direct Placement of Common Stock
  • Nov 8, 2004
    Insmed Incorporated Reports Financial Results for Third Quarter and First Nine-Months of 2004
  • Oct 26, 2004
    Insmed to Present at Rodman and Renshaw Healthcare Conference October 28, 2004; Presentation to Be Webcast Live
  • Oct 21, 2004
    Insmed and Tzamal Pharma Announce Agreement for the Promotion and Distribution of SomatoKine in Middle Eastern Territories
  • Oct 19, 2004
    Insmed Announces Initiation of Clinical Study of Small Molecule IGF-IR Tyrosine Kinase Inhibitor
  • Sep 13, 2004
    Insmed Reports Results from Nine Months of SomatoKine Therapy for a Patient with Extreme Insulin Resistance at the 43rd Meeting of the European Society of Pediatric Endocrinology
  • Sep 8, 2004
    Insmed Initiates Phase I Clinical Study for Novel Anti-Tumor Protein
  • Aug 17, 2004
    Insmed Requests Halt of Trading of Its Common Stock on the Berlin-Bremen Stock Exchange; Company Also Initiates Short Selling Audit
  • Jul 28, 2004
    Insmed Incorporated Reports Financial Results for Second Quarter and First Half of 2004
  • Jul 21, 2004
    Insmed to Report Second Quarter Financial Results;Wednesday, July 28
  • Jul 20, 2004
    Insmed Reports Update on Pivotal Clinical Trial with SomatoKine: Statistically Significant Increase in Growth Rate Observed at Six Months
  • Jul 19, 2004
    Insmed Receives Authorization for Reimbursement for SomatoKine Named Patient Program from France and Italy; Newly Appointed Chief Business Officer Expands the Named Patient Program
  • Jul 19, 2004
    Insmed Announces Two Independent Presentations at the National Cancer Institutes 12th Annual Meeting of SPORE
  • May 13, 2004
    Breast Cancer Center of Excellence Awarded $10 Million Department of Defense Grant; rhIGFBP-3 Selected as a Candidate Agent in Clinical Trials
  • May 11, 2004
    Insmed to Present at Rodman and Renshaw Healthcare Conference May 13, 2004; Presentation to Be Webcast Live
  • May 5, 2004
    Insmed Incorporated Reports Financial Results for First Quarter of 2004
  • Apr 29, 2004
    Insmed Incorporated to Webcast First Quarter Earnings Conference Call; Thursday, May 6, at 11:00 a.m. ET - 10:00 a.m. CT
  • Apr 14, 2004
    Insmed Acquires Manufacturing Facility from Baxter International
  • Mar 23, 2004
    Insmed to Present at Wells Fargo Securities Healthcare Conference
  • Mar 23, 2004
    Insmed to Present at Wells Fargo Securities Healthcare Conference; Presentation to Be Webcast Live
  • Feb 11, 2004
    Insmed Incorporated Reports Improved Financial Results for Fourth Quarter 2003 and Twelve-Months Ended December 31, 2003
  • Feb 4, 2004
    Insmed Inc. to Webcast Fourth Quarter Earnings Conference Call; Wednesday, February 11, at 11:00 a.m. ET - 10:00 a.m. CT
  • Jan 26, 2004
    Insmed Obtains Patent Rights for Extreme Insulin Resistance From Fujisawa
  • Dec 15, 2003
    Insmed Receives FDA Orphan Drug Designation For rhIGF-I/rhIGFBP-3, SomatoKine, for Extreme Insulin Resistance
  • Dec 3, 2003
    Insmed Presents Positive Data on Anti-Cancer Drug Candidate to San Antonio Breast Cancer Symposium
  • Dec 2, 2003
    rhIGF-I/rhIGFBP-3, SomatoKine, Found to Delay the Onset of Type I Diabetes
    rhIGF-I/rhIGFBP-3, SomatoKine, Found to Delay the Onset of Type I Diabetes
  • Nov 17, 2003
    Insmed Presents Positive Data on Anti-Cancer Drug Candidate to AACR-NCI-EORTC
  • Nov 5, 2003
    Insmed to Present Cancer Data to CaP Cure, the Prostate Cancer Foundation
  • Nov 5, 2003
    Insmed Incorporated Reports Financial Results for Third Quarter 2003 and Nine-Months Ended September 30, 2003
  • Oct 28, 2003
    Insmed Incorporated to Webcast Third Quarter Earnings Conference Call; Wednesday, November 5, at 11:00 a.m. ET - 10:00 a.m. CT
  • Oct 16, 2003
    Insmed to Present to Rodman and Renshaw Healthcare Conference; Presentation to be Webcast Live
    Insmed to Present to Rodman and Renshaw Healthcare Conference; Presentation to be Webcast Live
Show 5102550100 per page
  • «
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy